Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.

Oncogene - 23 Feb 2006

Chen Y-R, Fu Y-N, Lin C-H, Yang S-T, Hu S-F, Chen Y-T, Tsai S-F, Huang S-F

Abstract excerpt

Mutations in the kinase domain of epidermal growth factor receptor (EGFR) are associated with clinical responsiveness to gefitinib in patients with non-small-cell lung cancers (NSCLC). Recently, we have identified many novel EGFR mutations in NSCLC tissues. In this study, we found that gefitinib could suppress the tyrosine phosphorylation of most EGFR mutants better than the wild-type receptor. However, gefitinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to COS Cells
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to EGF gene

Share to Lung Neoplasms

Share to Mutation

Share to Phosphorylation

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 16205628
DOI: 10.1038/sj.onc.1209159

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.PMID 16205628Read ↗

EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.Semantic proximity Read ↗

Inhibition of mutant EGF receptors by gefitinib: targeting an Achilles' heel of lung cancer.Semantic proximity Read ↗

Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors.Semantic proximity Read ↗

Ligand-Independent EGFR Signaling.Semantic proximity Read ↗

Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor.Semantic proximity Read ↗

Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis.Semantic proximity Read ↗

Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutationsSemantic proximity Read ↗

Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity.Semantic proximity Read ↗

Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations.Semantic proximity Read ↗

Mass Spectrometry Mapping of Epidermal Growth Factor Receptor Phosphorylation Related to Oncogenic Mutations and Tyrosine Kinase Inhibitor SensitivitySemantic proximity Read ↗

An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression.Semantic proximity Read ↗

Activating ERBB4 mutations in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.